Search results
AF and Mortality in MI Patients
Added:
1 year ago
Article
Added:
6 months ago
Source:
Radcliffe Cardiology
The long-term utility of beta-blockers following an uncomplicated myocardial infarction (MI) remains a subject of clinical debate. New secondary results from the AβYSS trial (Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization) reveal that interrupting this therapy leads to sustained…
View more
Added:
1 year ago
AHA Conference 2024 — New insights from the NUDGE-FLU Program on electronic nudges to increase influenza vaccination amongst patients with a history of myocardial infarction.Dr Harriette Van Spall (McMaster University, CA) sits down with the principal investigator of the NUDGE-FLU trial, (NCT05542004) Dr Tor Biering-Sørensen, to discuss the latest insights and data.NUDGE-FLU is a prospective,…
View more
Added:
3 days ago
Source:
Arrhythmia Academy
A new substudy of the VANISH2 trial suggests that for patients with prior myocardial infarction and ventricular tachycardia (VT) who are eligible for sotalol, catheter ablation leads to better outcomes than antiarrhythmic drug (AAD) therapy.¹ For patients eligible only for amiodarone, efficacy was comparable, but amiodarone was associated with a significant increase in adverse events…
View more
Added:
1 month ago
Added:
1 year ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,…
View more
Added:
2 years ago
Added:
2 years ago
In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023.Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.Drs Kalra and Nijjer share their…
View more
Added:
1 year ago
Added:
2 weeks ago
Source:
Radcliffe Cardiology
A prespecified substudy of the VANISH2 trial suggests first-line catheter ablation is superior to sotalol for reducing arrhythmia events in eligible patients with ischaemic cardiomyopathy and ventricular tachycardia (VT).¹ In patients ineligible for sotalol, ablation showed comparable efficacy to amiodarone but with a markedly better long-term safety profile.MethodologyThe VANISH2 (Ventricular…
View more